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Like baby chicks, stem cells need a nest—a niche within the body where they 
reside and self-renew. Oguro et al. (page  <ArtRef vol=”203” Iss=”10”>2247</ArtRef>) find that, for blood stem 
cells, this nest is built by the same gene silencer that also helps them self-renew.
This silencer is Bmi1, which turns off two cell cycle inhibitor genes, 
Ink4a and Arf, to promote the self-renewal of hematopoietic stem cells 
(HSCs). Oguro et al. showed that defective HSC self-renewal in Bmi1-
deficient mice can be restored by deletion of these cell cycle regulators, as 
previously observed in neural stem cells. But the new results show that HSC 
levels gradually decline as these mice age.
The authors wondered whether the progressive HSC problem might be due 
to defects in the HSC niche—the bone marrow microenvironment. Indeed, they 
found that development of the spongy meshwork structure of bone marrow in 
mice lacking Bmi1 was severely impaired and failed to support renewal of 
wild-type HSCs. The defects suggested that Bmi1 might be required for normal 
growth of the niche cells. The group showed that the proliferation of bone-
forming osteoblasts was impaired in the absence of Bmi1. These findings fit 
well with previous reports that osteoblasts are important components of 
the HSC niche.
The defective niche 
was not rescued by 
deletion of Ink4a and Arf. 
Nest building in the bone 
marrow is therefore likely 
to require silencing of 
other Bmi1 targets. 
The team is currently 
searching for what those 
targets might be. 
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Lysosomal storage disorders prevent the proper action of some natural killer T 
(NKT) cells, according to Gadola et al. (page  <ArtRef vol=”203” Iss=”10”>2293</ArtRef>).
NKT cells recognize glycosphingolipid (GSL) antigens presented on the 
surface of various cell types. Recognition of endogenous GSL antigens leads to 
the positive selection of NKT cells in the thymus. Once in the periphery, NKT 
cells can induce an immune response if presented with GSLs of foreign origin.
The overaccumulation of GSLs in lysosomes is a common feature of 
lysosomal storage disorders. Here, Gadola and colleagues show that this 
congestion impairs the intracellular processing and presentation of GSLs in the 
antigen-presenting cells of mouse models of lysosomal storage disorders.
The authors reasoned that, given their reliance on GSLs for selection, NKT 
cells might be impaired in the disease model mice. They found that, although the 
mice had normal NKT cells in terms of development and function, the numbers of 
these cells were dramatically reduced compared with wild-type mice. The 
simplest explanation for the low numbers, says coauthor Frances Platt, is that the 
impaired presentation of endogenous GSLs in the thymus leads to fewer NKT 
cells making it through the positive selection stage.
The mouse models differ in the particular lysosomal component affected, 
but they all accumulate GSL in their lysosomes. It will thus be interesting to 
determine whether the broad spectrum of human GSL storage disorders also 
lack NKT cells and whether this defect could help explain in part the clinical 
heterogeneity of these disorders. 
<doi>10.1084/jem.20310iti3</doi><aid>jem.20310iti3</aid> <au> Ruth  William s</au><cor >ruth.w illi ams@ rock ef ell er.ed u< /cor >Weapons of 
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Patients with systemic lupus erythematosus 
(SLE) do not get rid of self-attacking B cells 
even when in symptom-free remission, report 
Yurasov et al. (page  <ArtRef vol=”203” Iss=”10”>2255</ArtRef>).
Patients with SLE suffer from chronic 
inflammation mainly of the connective tissues 
and organs. Treatment with immunosup-
pressants or cytotoxic drugs relieves the 
symptoms of SLE by depleting B cells, but 
these patients in remission are prone to fre-
quent flare-ups.
During normal B cell development, 
checkpoints identify and destroy cells that 
make antibodies against the self. Previous 
studies revealed high levels of self-reactive 
antibodies in patients with SLE compared 
with healthy people, but whether these cells 
persist in symptom-free remission patients 
was unknown.
Yurasov et al. used ELISA to look at the 
reactivity of individual B cell antibodies. 
They compared individual B cells from patients 
in remission with those from symptomatic 
patients as well as healthy individuals. 
Although patients in remission had fewer 
self-reactive B cells than symptomatic patients 
(34.25% versus 44.4%), they still had consid-
erably more than healthy individuals (19.7%). 
The B cells analyzed by the team were 
“naive” and thus immature, suggesting that 
checkpoint failures early in B cell develop-
ment are the cause of self-reactive antibodies 
in SLE.
The persistence of self-reactive B cells 
in remission patients might explain the 
occasional flare-ups and also suggests that, 
although the symptoms of SLE might disap-
pear in remission, the faulty checkpoints 
remain. 
Patients in remission have a lower percentage of 
autoreactive B cells (black) than do symptomatic 
SLE patients, but still considerably higher than 
healthy individuals.
Normal development of the bone marrow HSC 
niche (left) fails in the absence of Bmi1 (right).